001060 — JW Pharmaceutical Income Statement
0.000.00%
Last trade - 00:00- KR₩766bn
- KR₩885bn
- KR₩749bn
- 95
- 54
- 72
- 90
Annual income statement for JW Pharmaceutical, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 511,335 | 547,336 | 606,585 | 684,351 | 748,527 |
| Cost of Revenue | |||||
| Gross Profit | 161,119 | 177,526 | 234,376 | 287,955 | 335,542 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 531,853 | 549,419 | 576,285 | 628,923 | 648,223 |
| Operating Profit | -20,518 | -2,083 | 30,300 | 55,428 | 100,304 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -34,335 | -13,205 | 20,533 | 45,362 | 54,836 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -25,275 | -15,275 | -1,441 | 29,853 | 38,430 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -25,275 | -15,241 | -968 | 31,892 | 37,006 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | -24,785 | -14,381 | -916 | 30,312 | 35,096 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1,026 | -598 | 14.6 | 1,474 | 1,537 |
| Dividends per Share |